CardioInnovate360™
BioPharma research platform for cardiovascular solution development
Platform · Cloud SaaSCompany source
Company profile
About Cardio Diagnostics, Inc.
Cardio Diagnostics leads AI-driven heart care with innovative genetic-epigenetic technology for heart attack risk and heart disease prevention.
Company description Cardio Diagnostics, Inc. official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Work at Cardio Diagnostics, Inc.?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- cardiovascular disease
- coronary heart disease
- heart attack risk
- ischemia with no obstructive coronary arteries (INOCA)
Who it serves
- BioPharma
- Consultants
- Employers
- Health Systems
- Patients
- Provider Groups
- Providers
Deployment & integration
Cloud Saas · Other deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Multiple clinical solutions launched (Epi+Gen CHD, PrecisionCHD, HeartRisk, CardioInnovate360). Published validation studies in peer-reviewed journals.
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Epi+Gen CHD™
Three-year coronary heart disease event risk assessment blood test
Software · Cloud SaaSCompany source
HeartRisk™
Real-time population cardiovascular risk intelligence platform
Platform · Cloud SaaSCompany source
PrecisionCHD™
Coronary heart disease detection and management blood test
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Personalized medicine for cardiovascular diseases: how next generation epigenetic technologies can contribute?Epigenomics · Jul 1, 2025
The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs.Advances in therapy · Jun 1, 2024
Validation of an Integrated Genetic-Epigenetic Test for the Assessment of Coronary Heart Disease.Journal of the American Heart Association · Nov 21, 2023
Precision epigenetics provides a scalable pathway for improving coronary heart disease care globally.Epigenomics · Aug 1, 2023
The Reversion of the Epigenetic Signature of Coronary Heart Disease in Response to Smoking Cessation.Genes · Jun 8, 2023
Additive and Interactive Genetically Contextual Effects of HbA1c on cg19693031 Methylation in Type 2 Diabetes.Genes · Apr 13, 2022
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
2x more sensitive than conventional risk calculators
Epi+Gen CHD for 3-year CHD event prediction
39% average sensitivity of conventional risk calculators
Comparison baseline for traditional methods
80-90% of CVD estimated preventable
Through early detection and proactive management
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Cardio Diagnostics, Inc.
Recent articles published on Cardio Diagnostics, Inc.'s official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.